FIGO 2018 Stage IB2 Cervical Cancer Treated With Neoadjuvant Chemotherapy Followed by Fertility Sparing Surgery

Inclusion Criteria: Part 1 - Eligibility Criteria for Neoadjuvant Chemotherapy * Patients must have histologically confirmed invasive cervical cancer with adenocarcinoma, adenosquamous or squamous histology and FIGO 2018 IB2 measuring \>2 cm - ≤4 cm by radiological imaging (MRI). * Patients must be premenopausal and wish to preserve fertility. * At time of registration, patient may not have had any prior therapy to treat their cancer lesion. * Eastern Cooperative Group (ECOG) performance status ≤ 2. * Within 7 days of the proposed start of treatment, patients must have normal organ and marrow function. * No evidence of active uncontrolled infection (patients on antibiotics are eligible). * Patient must have disease that is measurable per the Response Evaluation Criteria in Solid Tumors (RECIST) 1.1. * Ability to understand and willing to sign a written informed consent document. * Patients must agree to use effective contraceptive methods prior to study entry, during study participation, and for at least one year after the fertility-sparing surgery (FSS) procedure. A serum pregnancy test within 72 hours prior to study registration is required. Part 2 - Eligibility Criteria for Fertility Sparing Surgery (FSS) * Completed 3 cycles of neo-adjuvant chemotherapy and achieved a complete response (CR) or partial response (PR) with reduction of the lesion to \<2 cm on physical examination and MRI. Exclusion Criteria: Part 1 - Exclusion Criteria for Neoadjuvant Chemotherapy * P…